Combination Therapy in ADHD: When and How to Augment Treatment Safely

As attention-deficit/hyperactivity disorder (ADHD) management becomes more nuanced, combination therapy is gaining attention as a pragmatic solution for patients who experience suboptimal outcomes or intolerable side effects on monotherapy. This article examines the clinical rationale, evolving data, and practical considerations for combining stimulants with non-stimulants—such as atomoxetine, guanfacine, clonidine, and viloxazine—in pediatric and adolescent populations.

Why Consider a Drug Combination for Your Patients With ADHD?

Patients with ADHD treated with stimulant or non-stimulant monotherapies may not respond to treatment. Some may experience less improvement than expected, while others may experience effective symptom control but discontinue because they cannot tolerate adverse effects.¹ Stimulants, the most frequently prescribed first-line medication,² come in long-acting and short-acting formulations, but even the long-acting formulations fail to provide around-the-clock duration of coverage.³ As long-acting agents wear off, patients may experience a rebound of symptoms.⁴ A short-acting agent can be given late in the day when a long-acting agent would be expected to wear off, but the activating effects of stimulant combinations can disturb sleep.⁵ In such situations, combination regimens, most notably of stimulants with non-stimulants, can be useful.³

In a retroactive analysis of 78 849 children and adolescents with ADHD, 91.9% of children and 92.4% of adolescents received a stimulant, while 9.7% of children and 8.8% of adolescents received a non-stimulant.² A total of 10.5% of pediatric patients and 10.5% of adolescents received a combination of ≥2 medications as their first treatment regimen.² At the end of 12 months, 40.9% of children and 32.2% of adolescents were still taking their initial regimen.² The proportion of patients receiving combinations increased over time. Among individuals who received a second regimen, 26.2% of children and 24.4% of adolescents were given combination therapy, and for third regimens, the proportions receiving combination therapy increased to 26.4% in children and 22.6% in adolescents.² 

Why Stimulant–Non-Stimulant Combinations?

Non-stimulants can play an important role in managing both core symptoms and common comorbidities, especially when stimulants are ineffective or may cause worsening symptoms. Atomoxetine, guanfacine, and clonidine gradually enhance noradrenergic activity to offer continuous relief of ADHD symptoms and help control symptoms after stimulants wear off. Unlike stimulants, they are uncontrolled substances and, as such, are potential first-line options in patients with histories of substance misuse as well as disruptive behavior and tic/Tourette's disorders.⁴ Guanfacine and clonidine can also be prescribed in patients with sleep disorders, to which stimulants may contribute.⁴

Viloxazine, a recent entrant to the ADHD armamentarium, is classified as a serotonin-norepinephrine reuptake inhibitor, with some researchers suggesting that the serotonergic element is an important, if not predominant, aspect of its activity.⁶ Viloxazine does not cause significant cardiovascular effects, most notably effects on pulse and blood pressure, seen with stimulants and other non-stimulants.⁴ Furthermore, several studies have shown viloxazine to be effective and well tolerated in pediatric patients with ADHD.⁴

Methylphenidate/Atomoxetine

A systematic review examined 6 studies conducted between 2012 and 2024 on the combined effects of methylphenidate and atomoxetine.⁷ Of 3 studies reporting efficacy results, 2 reported improved outcomes with combination therapy in treatment-resistant patients, while 1 found no difference between atomoxetine monotherapy and combination therapy.⁷ While the 3 studies did not show large benefits, there was a small subpopulation that benefited from the combination.⁷ Four studies assessed adherence, with 3 showing improved adherence with combination therapy and 1 reporting that the combination was associated with methylphenidate discontinuation.⁷

Methylphenidate/Guanfacine

In a double-blind, randomized trial, 207 children aged 7 to 14 years with ADHD received guanfacine (1 to 3 mg/day), methylphenidate extended release (5 to 20 mg/day), or a combination of both for 8 weeks.⁸ Significant main effects were observed across treatment groups for total ADHD-RS-IV scores and inattentive symptoms (both P = 0.0001).⁸ The combination therapy produced slightly greater reductions in inattentive symptoms compared with either monotherapy (versus methylphenidate, P = 0.05; versus guanfacine, P = 0.02) and showed a higher rate of positive clinical response according to the Clinical Global Impression-Improvement scale (P = 0.01).⁸ All treatments were well tolerated, but sedation-related adverse events—eg, somnolence, lethargy, and fatigue—were more frequent in both groups receiving guanfacine.⁸

Psychostimulants/Viloxazine

One study evaluated the safety, tolerability, and efficacy of viloxazine extended-release (ER) in combination with psychostimulants in 56 children and adolescents (ages 6 to 17 years) with ADHD and inadequate stimulant response.⁹ Viloxazine ER was taken in the morning (weeks 1 to 4) or evening (weeks 5 to 8).⁹ Forty-eight participants (85.7%) completed the study; only 2 (3.6%) discontinued due to adverse events.⁹ Common side effects included headache (17.9%), decreased appetite (12.5%), and upper respiratory infection (10.7%).⁹ ADHD Rating Scale-5 severity scores improved by an average of -13.5 at week 4 and -18.2 at week 8 (P < 0.0001 at both timepoints).⁹ CGI-S scores improved by -0.9 and -1.4, respectively (P < 0.0001 at both timepoints).⁹ 

Conclusion

Although combination regimens for ADHD are widely prescribed, they remain under-researched. Most randomized controlled trials are not designed to evaluate the multimodal treatment strategies recommended in clinical guidelines.¹⁰ One reason may be that the US Food and Drug Administration (FDA) has not approved the use of more than one anti-ADHD medication; therefore, such regimens may not be covered by insurance.¹ Moreover, children have historically been the primary population treated for ADHD, and clinicians may be cautious about prescribing combination therapies without sufficient supporting evidence.¹ In effect, this caution helps perpetuate a cycle in which limited use leads to limited studies, and limited studies reinforce the limited use. However, interest in combination regimens for ADHD is growing,¹ and a modest body of research showing benefits of stimulant–non-stimulant combinations is emerging.^7-9 Continued research is needed to ensure that scientific studies mirror real-world clinical practice.⁴

References:

1. Bahn GH, Seo K. Combined medication with stimulants and non-stimulants for attention-deficit/hyperactivity disorder. Clin Psychopharmacol Neurosci. 2021;19(4):705-711. doi:10.9758/cpn.2021.19.4.705
2. Schein J, Childress A, Adams J, et al. Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysis. BMC Psychiatry. 2022;22(1):555. doi:10.1186/s12888-022-04188-4
3. Cutler AJ, Mattingly GW, Jain R, O'Neal W. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectr. 2022;27(2):199-207. doi:10.1017/S1092852920001984
4. Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther. 2022:230:107940. doi:10.1016/j.pharmthera.2021.107940
5. Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; February 23, 2016.
6. Yu C, Garcia-Olivares, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020:12:285-300. doi:10.2147/JEP.S256586
7. Cheng T, Boileau. Effectiveness of atomoxetine and stimulant combination in attention-deficit/hyperactivity disorder (ADHD) treatment: a systematic review. Cureus. 2025;17(2):e79378. doi:10.7759/cureus.79378
8. McCracken JT, McGough JJ, Loo SK, et al. Combined stimulant and guanfacine administration in attention-deficit/hyperactivity disorder: a controlled, comparative study. J Am Acad Child Adolesc Psychiatry. 2016;55(8):657-666.e1. doi:10.1016/j.jaac.2016.05.015 
9. Childress A, Asubonteng K, Cox G, et al. Viloxazine extended-release administered with psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder: a phase 4, open-label trial. J Child Adolesc Psychopharmacol. 2025;35(3):155-166. doi:10.1089/cap.2024.0138
10. Wong ICK, Banaschewski T, Buitelaar J, et al. Emerging challenges in pharmacotherapy research on attention deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. Lancet Psychiatry. 2019;6(6):528-537. doi:10.1016/S2215-0366(19)30096-3